Summary

Hepatitis Therapeutics Market – Scope of Report
TMR’s report on the global hepatitis therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global hepatitis therapeutics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global hepatitis therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the hepatitis therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global hepatitis therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global hepatitis therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global hepatitis therapeutics market.

The report delves into the competitive landscape of the global hepatitis therapeutics market. Key players operating in the global hepatitis therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global hepatitis therapeutics market profiled in this report.

Key Questions Answered in Global hepatitis therapeutics Market Report
• What is the sales/revenue generated by hepatitis therapeutics across all regions during the forecast period?
• What are the opportunities in the global hepatitis therapeutics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Hepatitis Therapeutics Market – Research Objectives and Research Approach
The comprehensive report on the global hepatitis therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global hepatitis therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global hepatitis therapeutics market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Hepatitis Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hepatitis Therapeutics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Hepatitis Therapeutics Market Analysis and Forecast, by Disease
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease, 2017–2031
6.3.1. Hepatitis A
6.3.2. Hepatitis B
6.3.3. Hepatitis C
6.3.4. Others
6.4. Market Attractiveness Analysis, by Disease
7. Global Hepatitis Therapeutics Market Analysis and Forecast, by Drug Class
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug Class, 2017–2031
7.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
7.3.2. NS5A Inhibitor
7.3.3. Multi-class Combination
7.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
7.3.5. Interferon & Ribavirin
7.3.6. Others
7.4. Market Attractiveness Analysis, by Drug Class
8. Global Hepatitis Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Drug Class
9. Global Hepatitis Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Hepatitis Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Disease, 2017–2031
10.3.1. Hepatitis A
10.3.2. Hepatitis B
10.3.3. Hepatitis C
10.3.4. Others
10.4. Market Value Forecast, by Drug Class, 2017–2031
10.4.1. Nucleotide Analog Reverse Transcriptase Inhibitor
10.4.2. NS5A Inhibitor
10.4.3. Multi-class Combination
10.4.4. Nucleotide Analog NS5B Polymerase Inhibitor
10.4.5. Interferon & Ribavirin
10.4.6. Others
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Disease
10.7.2. By Drug Class
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Hepatitis Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Disease, 2017–2031
11.3.1. Hepatitis A
11.3.2. Hepatitis B
11.3.3. Hepatitis C
11.3.4. Others
11.4. Market Value Forecast, by Drug Class, 2017–2031
11.4.1. Nucleotide Analog Reverse Transcriptase Inhibitor
11.4.2. NS5A Inhibitor
11.4.3. Multi-class Combination
11.4.4. Nucleotide Analog NS5B Polymerase Inhibitor
11.4.5. Interferon & Ribavirin
11.4.6. Others
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Disease
11.7.2. By Drug Class
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Hepatitis Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Disease, 2017–2031
12.3.1. Hepatitis A
12.3.2. Hepatitis B
12.3.3. Hepatitis C
12.3.4. Others
12.4. Market Value Forecast, by Drug Class, 2017–2031
12.4.1. Nucleotide Analog Reverse Transcriptase Inhibitor
12.4.2. NS5A Inhibitor
12.4.3. Multi-class Combination
12.4.4. Nucleotide Analog NS5B Polymerase Inhibitor
12.4.5. Interferon & Ribavirin
12.4.6. Others
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Disease
12.7.2. By Drug Class
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Hepatitis Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Disease, 2017–2031
13.3.1. Hepatitis A
13.3.2. Hepatitis B
13.3.3. Hepatitis C
13.3.4. Others
13.4. Market Value Forecast, by Drug Class, 2017–2031
13.4.1. Nucleotide Analog Reverse Transcriptase Inhibitor
13.4.2. NS5A Inhibitor
13.4.3. Multi-class Combination
13.4.4. Nucleotide Analog NS5B Polymerase Inhibitor
13.4.5. Interferon & Ribavirin
13.4.6. Others
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Disease
13.7.2. By Drug Class
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Hepatitis Therapeutics Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Disease, 2017–2031
14.3.1. Hepatitis A
14.3.2. Hepatitis B
14.3.3. Hepatitis C
14.3.4. Others
14.4. Market Value Forecast, by Drug Class, 2017–2031
14.4.1. Nucleotide Analog Reverse Transcriptase Inhibitor
14.4.2. NS5A Inhibitor
14.4.3. Multi-class Combination
14.4.4. Nucleotide Analog NS5B Polymerase Inhibitor
14.4.5. Interferon & Ribavirin
14.4.6. Others
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Disease
14.7.2. By Drug Class
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Gilead Sciences, Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. F. Hoffmann-La Roche, Ltd.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Bristol Myers Squibb
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Merck & Co., Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. AbbVie Inc.
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. NATCO Pharma Limited
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Zydus Cadila
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Hetero Healthcare Limited
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. LAURUS Labs
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Cipla, Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview